Browse LTA4H

Summary
SymbolLTA4H
Nameleukotriene A4 hydrolase
Aliases LTA-4 hydrolase; Leukotriene A(4) hydrolase; Leukotriene A-4 hydrolase
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm.
Domain PF09127 Leukotriene A4 hydrolase
PF01433 Peptidase family M1
Function

Epoxide hydrolase that catalyzes the final step in the biosynthesis of the proinflammatory mediator leukotriene B4. Has also aminopeptidase activity.

> Gene Ontology
 
Biological Process GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006636 unsaturated fatty acid biosynthetic process
GO:0006690 icosanoid metabolic process
GO:0006691 leukotriene metabolic process
GO:0016053 organic acid biosynthetic process
GO:0019370 leukotriene biosynthetic process
GO:0033559 unsaturated fatty acid metabolic process
GO:0043171 peptide catabolic process
GO:0044283 small molecule biosynthetic process
GO:0046394 carboxylic acid biosynthetic process
GO:0046456 icosanoid biosynthetic process
GO:0072330 monocarboxylic acid biosynthetic process
GO:1901565 organonitrogen compound catabolic process
Molecular Function GO:0004177 aminopeptidase activity
GO:0004301 epoxide hydrolase activity
GO:0004463 leukotriene-A4 hydrolase activity
GO:0008235 metalloexopeptidase activity
GO:0008237 metallopeptidase activity
GO:0008238 exopeptidase activity
GO:0016801 hydrolase activity, acting on ether bonds
GO:0016803 ether hydrolase activity
GO:0033218 amide binding
GO:0042277 peptide binding
GO:0070006 metalloaminopeptidase activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00590 Arachidonic acid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-2142753: Arachidonic acid metabolism
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-6798695: Neutrophil degranulation
R-HSA-2142691: Synthesis of Leukotrienes (LT) and Eoxins (EX)
Summary
SymbolLTA4H
Nameleukotriene A4 hydrolase
Aliases LTA-4 hydrolase; Leukotriene A(4) hydrolase; Leukotriene A-4 hydrolase
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LTA4H and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolLTA4H
Nameleukotriene A4 hydrolase
Aliases LTA-4 hydrolase; Leukotriene A(4) hydrolase; Leukotriene A-4 hydrolase
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LTA4H in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 1.07; FDR: 0.001770 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolLTA4H
Nameleukotriene A4 hydrolase
Aliases LTA-4 hydrolase; Leukotriene A(4) hydrolase; Leukotriene A-4 hydrolase
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LTA4H in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2290.31
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1560.949
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2850.871
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1550.567
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.120.951
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1990.936
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1830.677
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0450.981
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.4660.826
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4020.828
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8110.777
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.030.676
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LTA4H in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLTA4H
Nameleukotriene A4 hydrolase
Aliases LTA-4 hydrolase; Leukotriene A(4) hydrolase; Leukotriene A-4 hydrolase
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LTA4H. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLTA4H
Nameleukotriene A4 hydrolase
Aliases LTA-4 hydrolase; Leukotriene A(4) hydrolase; Leukotriene A-4 hydrolase
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LTA4H. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LTA4H.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLTA4H
Nameleukotriene A4 hydrolase
Aliases LTA-4 hydrolase; Leukotriene A(4) hydrolase; Leukotriene A-4 hydrolase
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LTA4H. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLTA4H
Nameleukotriene A4 hydrolase
Aliases LTA-4 hydrolase; Leukotriene A(4) hydrolase; Leukotriene A-4 hydrolase
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LTA4H expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLTA4H
Nameleukotriene A4 hydrolase
Aliases LTA-4 hydrolase; Leukotriene A(4) hydrolase; Leukotriene A-4 hydrolase
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LTA4H and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLTA4H
Nameleukotriene A4 hydrolase
Aliases LTA-4 hydrolase; Leukotriene A(4) hydrolase; Leukotriene A-4 hydrolase
Chromosomal Location12q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LTA4H collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting LTA4H.
ID Name Drug Type Targets #Targets
DB01197CaptoprilSmall MoleculeACE, BDKRB1, LTA4H, MMP2, MMP95
DB02062N-[3-[(1-Aminoethyl)(Hydroxy)Phosphoryl]-2-(1,1'-Biphenyl-4-Ylmethyl)Propanoyl]AlanineSmall MoleculeLTA4H, MME2
DB023523-(Benzyloxy)Pyridin-2-AmineSmall MoleculeLTA4H, MAPK142
DB03366ImidazoleSmall MoleculeAK2, CYCS, DMC1, GPHN, LTA4H, MB, MYO1E, NOS2, PIM19
DB03424UbenimexSmall MoleculeLTA4H1
DB05177DG051Small MoleculeLTA4H1
DB068285-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indoleSmall MoleculeLTA4H1
DB06851N-(pyridin-3-ylmethyl)anilineSmall MoleculeLTA4H1
DB06917(4-fluorophenyl)(pyridin-4-yl)methanoneSmall MoleculeLTA4H1
DB070941-(2,2'-bithiophen-5-yl)methanamineSmall MoleculeLTA4H1
DB07099N-[4-(benzyloxy)phenyl]glycinamideSmall MoleculeLTA4H1
DB07102(2S)-2-amino-5-oxo-5-[(4-phenylmethoxyphenyl)amino]pentanoic acidSmall MoleculeLTA4H1
DB071044-amino-N-[4-(benzyloxy)phenyl]butanamideSmall MoleculeLTA4H1
DB07196N-methyl-1-(2-thiophen-2-ylphenyl)methanamineSmall MoleculeLTA4H1
DB07237{4-[(2R)-pyrrolidin-2-ylmethoxy]phenyl}(4-thiophen-3-ylphenyl)methanoneSmall MoleculeLTA4H1
DB07258(R)-pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanolSmall MoleculeLTA4H1
DB072591-(4-thiophen-2-ylphenyl)methanamineSmall MoleculeLTA4H1
DB07260N-benzyl-4-[(2R)-pyrrolidin-2-ylmethoxy]anilineSmall MoleculeLTA4H1
DB072924-(2-amino-1,3-thiazol-4-yl)phenolSmall MoleculeLTA4H1
DB08040N-[(2R)-2-benzyl-4-(hydroxyamino)-4-oxobutanoyl]-L-alanineSmall MoleculeLTA4H1
DB084665-[2-(4-hydroxyphenyl)ethyl]benzene-1,3-diolSmall MoleculeLTA4H1
DB11781TosedostatSmall MoleculeLTA4H, NPEPPS2